Tomo Tadashi
Department of Nephrology, Oita University Hospital, Oita University, Hasama-machi, Oita, Japan.
Contrib Nephrol. 2011;173:44-52. doi: 10.1159/000328945. Epub 2011 Aug 8.
In the present study, we investigated the effect of hemodialysis (HD) with high-performance membrane filter (HPM-HD) using acetate-free bicarbonate dialysis (AFD) fluid on bioincompatibility as represented by inflammatory markers in patients undergoing maintenance HD therapy and compared it with conventional acetate-containing bicarbonate dialysis (ACD) fluid. A total of 36 maintenance HD patients were registered for study during the 4-month study period (22 males and 14 females, aged 63.5 ± 10.2 years, mean duration of dialysis 12.2 ± 8.6 years, chronic glomerular nephritis in 27 patients, diabetic nephropathy in 6 patients, and nephrosclerosis in 3 patients). These patients were subjected to ACD for the first 2 months followed by AFD fluid for the latter 2 months. Predialysis blood pH and bicarbonate were examined after each of the first and latter 2-month period. Blood variables of C-reactive protein (CRP) and interleukin-6 (IL-6) or fetuin-A were also determined. The filters (membrane surface area, raw material), the conditions of HD (blood flow rate, dialysate flow rate, dialysis time, dry weight) and drug regimen including erythrocyte-simulating agent (drug type, dosage) were unchanged throughout the study. There appeared to be significantly higher levels of predialysis blood pH and bicarbonate in the AFD phase than in the ACD phase. Blood CRP and IL-6 levels were significantly decreased in the AFD group as compared with those seen in the ACD group. From these results, it can be suggested that HPM-HD using AFD fluid contributes to correcting metabolic acidosis and alleviating microinflammation in HD patients.
在本研究中,我们调查了使用无醋酸盐碳酸氢盐透析(AFD)液的高性能膜滤器血液透析(HD)(HPM-HD)对维持性HD治疗患者炎症标志物所代表的生物不相容性的影响,并将其与传统的含醋酸盐碳酸氢盐透析(ACD)液进行比较。在为期4个月的研究期间,共有36例维持性HD患者登记参加研究(22例男性和14例女性,年龄63.5±10.2岁,平均透析时间12.2±8.6年,27例慢性肾小球肾炎患者,6例糖尿病肾病患者,3例肾硬化患者)。这些患者在前2个月接受ACD治疗,后2个月接受AFD液治疗。在第1个和后2个月的每个时间段结束后检查透析前血液pH值和碳酸氢盐。还测定了C反应蛋白(CRP)、白细胞介素-6(IL-6)或胎球蛋白-A的血液变量。在整个研究过程中,滤器(膜表面积、原材料)、HD条件(血流速度、透析液流速、透析时间、干体重)以及包括促红细胞生成剂在内的药物治疗方案(药物类型、剂量)均未改变。AFD阶段透析前血液pH值和碳酸氢盐水平似乎明显高于ACD阶段。与ACD组相比,AFD组血液CRP和IL-6水平显著降低。从这些结果可以看出,使用AFD液的HPM-HD有助于纠正HD患者的代谢性酸中毒并减轻微炎症。